Lucid Diagnostics (NasdaqCM:LUCD) Q4 2025 Earnings call March 26, 2026 08:30 AM ET Company ParticipantsDennis McGrath - CFOJeremy Pearlman - Senior Research AssociateLishan Aklog - Chairman and CEOMatt Riley - VP of Investor RelationsConference Call ParticipantsKyle Mikson - Managing Director and Senior Research AnalystMark Massaro - Managing Director and Life Science and Diagnostic Tools AnalystMike Matson - Senior AnalystOperatorGood morning, and welcome to the Lucid Diagnostics fourth quarter 2025 busine ...

Financial Data and Key Metrics Changes - For the full year 2025, the company reported record revenue of $981.3 million, representing a year-over-year growth of 4.5% and 3.8% on a currency neutral basis [4][5] - Adjusted EBITDA for the full year was $320.9 million, with a margin of 32.7%, both metrics exceeding the high end of guidance [5][25] - In Q4 2025, revenue reached $282.3 million, a year-over-year increase of 14.1% and 12.7% on a currency neutral basis [5][13] - Q4 adjusted EBITDA was $104.1 million, up 29.1% reported and 27.2% on a currency neutral basis, with a margin of 36.9% [5][25] Business Line Data and Key Metrics Changes - Creative revenue in Q4 was $149 million, up 4.6% year-on-year, driven by accelerated revenue from two large licensing deals, despite a 16% decline in agency revenue [20] - Editorial revenue for Q4 was $109.4 million, up 21.4% year-on-year, with growth across all four verticals: news, sport, entertainment, and archive [21][22] - Annual subscription revenue grew 1% year-over-year, with Premium Access, the largest subscription, up 4.1% in Q4 [18] Market Data and Key Metrics Changes - The Americas region saw a revenue increase of 20.8% in Q4 on a currency neutral basis, while EMEA was up 6.1% and APAC down 13% due to challenges in the agency business [17] - Active annual subscribers totaled 278,000 in Q4, down from 314,000 in the previous year, primarily due to the discontinuation of the free trial program [19] Company Strategy and Development Direction - The company aims to strengthen its recurring revenue base and expand long-term partnerships, as evidenced by securing significant multi-year licensing agreements [6][7] - Continued investment in machine learning capabilities to enhance content discovery and customer experience is a strategic focus [10] - The company is optimistic about future growth opportunities in video and custom AI training sets, indicating a proactive approach to evolving market demands [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's durable business model, highlighting strong customer relationships and a diversified revenue mix as key strengths [4][11] - The company anticipates a revenue range of $948 million to $988 million for 2026, reflecting a decline due to the timing of revenue recognition from large licensing agreements [32][34] - Management noted that the core business is expected to grow, excluding the impact of challenging year-on-year comparisons from the previous year [35] Other Important Information - The company reported a decrease in free cash flow to $7.7 million in Q4, attributed to higher cash interest expenses [27][28] - Total debt outstanding was $2.01 billion as of December 31, 2025, with a net leverage of 4.0x [29][30] Q&A Session Summary Question: Insights on licensing deals and their long-term applicability - Management highlighted the relevance of content in social media and large language models as key drivers for the licensing deals, indicating potential for more such agreements in the future [38][39] Question: Reasons for decline in active annual subscribers and retention rates - The decline in active annual subscribers was primarily due to the end of the free trial program, with expectations for retention rates to improve as the impact cycles through [40][42] Question: Clarification on 2026 revenue guidance and data licensing - Management clarified that the large deals recognized in Q4 are not purely data licensing deals, and while there is a pipeline for future deals, specifics are not included in the 2026 guidance [47][49]

Core Viewpoint - ICON Public Limited Company is facing internal scrutiny regarding accounting practices related to revenue recognition, leading to a delay in its financial results for Q4 and full-year 2025 [1][2] Financial Results and Guidance - The company plans to release its delayed financial results on or before April 30, 2026, and has withdrawn its previously issued full-year 2025 financial guidance due to an ongoing investigation by the Audit Committee [2] - Analysts had previously estimated Q4 2025 adjusted EPS to be between $3.27 and $3.32, with revenue expected around $2.00 to $2.01 billion, reflecting modest year-over-year declines [3] - Full-year 2025 consensus estimates for adjusted EPS were in the range of $12.99 to $13.03, with revenue expected between $8.05 and $8.11 billion, down from prior guidance [3] Market Reaction - Following the announcement of the delay and guidance withdrawal, ICON's shares experienced a significant sell-off, dropping approximately 30-40% and reaching multi-year lows in the $70-$90 range [3] Legal Investigations - Multiple law firms have initiated investigations into potential securities law violations, with alerts issued for investors who purchased shares prior to the news [4] Industry Context - ICON operates in the contract research organization (CRO) sector, providing clinical development services to pharmaceutical and biotechnology companies, and competes with firms like IQVIA and Labcorp [4] - The CRO industry relies heavily on accurate revenue recognition for long-term contracts, making the current issues particularly sensitive [4] Financial Metrics - The earnings yield has increased to around 7-8% or higher following the drop in share price, indicating significant uncertainty priced into the market valuation [5] - Trailing P/E ratio is approximately 13-20x, with a price-to-sales ratio around 1.6-1.9x, and enterprise value to sales at approximately 1.3-2.0x [7] - The debt-to-equity ratio stands at 0.38, indicating moderate leverage, while the current ratio is 1.06, suggesting adequate short-term liquidity [7] Future Outlook - The ongoing investigation and delay highlight risks in financial reporting for CROs, with investors awaiting clarity on restated prior periods and updated outlooks for 2025 and 2026 [6]

Core Insights - ICON plc is under investigation following an internal accounting probe that revealed potential revenue overstatements for fiscal years 2023 and 2024, estimated at up to 2% each year [1] - The company has delayed the release of its fourth-quarter and full-year 2025 financial results due to this investigation [1] Company Overview - ICON plc is one of the largest contract research organizations (CROs) globally, providing outsourced drug development and clinical trial management services to pharmaceutical and biotechnology companies [1] - The CRO industry relies on long-term service contracts, making accurate revenue recognition critical [1] Financial Impact - An overstatement of up to 2% on annual revenue, given ICON's reported full-year revenue exceeding $8 billion, could represent a discrepancy of approximately $160 million per year [1] - This discrepancy could materially affect earnings per share, operating margins, and year-over-year growth rates [1] Recent Financial Performance - In the third quarter of 2025, the company reported revenue of $2.043 billion, reflecting a year-on-year increase of 0.6% [1] - The previous year's comparison figures for this growth claim are now under review due to the ongoing investigation [1] Market Reaction - Following the February 12, 2026 disclosure, ICON plc's shares declined approximately 40%, resulting in the loss of billions in market capitalization [1] - The company had repurchased $750 million of its own shares in the first three quarters of 2025 and authorized an additional $1 billion repurchase program in the second quarter, which was presented against a backdrop of a "very strong" financial position [1]

Core Viewpoint - Icon Plc is experiencing a significant decline in share price due to an internal investigation into accounting practices and internal controls, which has raised concerns among investors [1][2] Financial Reporting and Investigation - The ongoing investigation, initiated by the Audit Committee, focuses on revenue recognition for fiscal years 2023 through 2025, with expectations of reporting one or more material weaknesses in internal controls [2][3] - Preliminary findings suggest that revenue for 2023 and 2024 may have been overstated by less than 2% in each year, leading to delays in normal reporting processes and the withdrawal of previously issued full-year 2025 guidance [3] Customer Impact and Operations - The company has stated that the review has not identified any customer impact and that operations continue to support global drug development programs [4] Company Overview - Icon provides integrated consulting, clinical development, commercialization, and post-marketing solutions to various organizations, including pharmaceutical and biotechnology companies [5] Stock Performance - The stock is trading 27.7% below its 20-day simple moving average (SMA) and 30.6% below its 50-day SMA, indicating a bearish trend, with shares down 28.62% over the past 12 months [6] - The Relative Strength Index (RSI) is at 23.81, indicating oversold conditions, while the MACD is below its signal line, suggesting continued bearish pressure [7]

Core Viewpoint - A securities class action lawsuit has been filed against Ardent Health, Inc. following significant adverse accounting adjustments of approximately $90 million, leading to a stock price decline of over 33% [1][7] Group 1: Lawsuit Details - The lawsuit seeks to represent investors who acquired Ardent securities between July 18, 2024, and November 12, 2025 [1] - The case is titled Postiwala v. Ardent Health, Inc. et al., and focuses on Ardent's disclosures regarding accounts receivable collectability and reserves [3] - The lead plaintiff deadline for the lawsuit is set for March 9, 2026 [2] Group 2: Allegations and Financial Impact - Allegations include that Ardent's leadership was aware of material weaknesses in internal controls related to revenue recognition and failed to disclose these issues [2] - The company reported a revenue decrease of $42.6 million due to a change in accounting estimates and a new revenue accounting system that recognizes reserves earlier [6] - An increase in total operating expenses as a percentage of total revenue was driven by a $47.2 million increase in professional liability reserves [6] Group 3: Market Reaction - Following the financial disclosures on November 12, 2025, Ardent's stock price fell by $4.75, representing a 33% decline [7] - The significant revenue reduction and reserve increase raised questions about whether these issues should have been disclosed to investors earlier [8]

Financial Data and Key Metrics Changes - The company's revenue for Q2 2025 was $5.1 million, a decrease of 38.5% compared to the same period in 2024, which had revenue of $8.3 million [4][10] - Year-to-date revenue reached $13.4 million, representing a 19.2% increase from the prior year period [5] - The net loss for Q2 2025 was $1.1 million, or $0.15 per share, compared to a net loss of $800,000, or $0.11 per share, in Q2 2024 [12] Business Line Data and Key Metrics Changes - Revenue from the CVD equipment segment decreased by $700,000, while the FCC segment saw a $600,000 decline [10] - The CVD equipment revenue decreased by 17.4% primarily due to lower revenues from contracts in progress [10] - FCC segment revenue was $1.4 million, down from $2.2 million in Q2 2024, attributed to fewer contracts in progress [11] Market Data and Key Metrics Changes - Orders for the second quarter were $4.5 million, driven by strong demand in the FCC segment for gas delivery equipment [5] - Total orders for 2025 were $7.3 million, significantly lower than $16.9 million in 2024 [5] - The backlog as of June 30, 2025, was $13.2 million, down from $13.8 million at March 31, 2025 [7] Company Strategy and Development Direction - The company is focused on growing its presence in key markets such as aerospace, defense, and industrial applications [7] - There is an ongoing commitment to expense management while pursuing new product launches, including the CVD4000 silicon carbide coating reactor system [8][10] - The company is exploring potential uses for silicon carbide in the nuclear energy market and pursuing opportunities in electric vehicle battery materials [7] Management's Comments on Operating Environment and Future Outlook - Management highlighted uncertainties related to proposed tariffs and reduced U.S. government funding as factors impacting business [5] - The company is actively monitoring customer demand and geopolitical landscapes to manage operating expenses [6] - Future profitability is contingent on new equipment orders and managing inflationary pressures [12] Other Important Information - Cash and cash equivalents as of June 30, 2025, were $7 million, down from $12.6 million at the end of 2024 [12] - The company believes its cash flow will be sufficient to meet working capital and capital expense requirements for the next twelve months [13] Q&A Session Summary Question: Inquiry about NDA client specifics - The client under the NDA is domestic, located in the United States, but the company has agreements with both domestic and international clients [18][19] Question: Impact of tariffs on orders - Tariffs affect the cost of goods sold, particularly for components sourced from Europe and Asia, but the company is managing these inflationary pressures [20] Question: Revenue recognition for July delivery - Revenue is recognized using the overtime concept, meaning it will be reported in the quarter when the product is manufactured [21]

Core Viewpoint - A class action lawsuit has been filed against 3D Systems Corporation and certain officers for alleged violations of federal securities laws during the Class Period from August 13, 2024, to May 12, 2025, seeking damages for misleading statements regarding the company's business and operations [1][8]. Company Overview - 3D Systems provides 3D printing and digital manufacturing solutions across various regions, earning revenue from two segments: Healthcare Solutions and Industrial Solutions [4]. - The Healthcare Solutions segment includes dental, medical devices, personalized health services, and regenerative medicine [4]. Regenerative Medicine Program - The Regenerative Medicine Program focuses on additive manufacturing for human organ transplantation, with a partnership with United Therapeutics Corporation aimed at developing 3D-printed lungs [5]. - Milestone criteria in the United Partnership are crucial for revenue recognition, and updates to these criteria affect the timing and probability of receiving milestone payments [6]. Financial Performance - The 3D printing industry has faced reduced customer spending, impacting sales; however, 3D Systems remains optimistic about future growth and has focused on gross margin expansion and operating expense improvements [7]. - For full-year 2025, the company projected revenue between $420 million and $435 million, indicating flat to modest growth, with a non-GAAP gross profit margin of 37% to 39% [7]. - In Q4 2024, 3D Systems reported a non-GAAP earnings-per-share of -$0.19 and sales revenue of $111 million, a 3.4% year-over-year decline [9]. - The company reported a full-year 2024 sales decrease of 10% to $440.1 million, attributed to lower hardware systems sales due to macroeconomic factors [9]. - In Q1 2025, revenue was $94.5 million, down 8% year-over-year, with a net loss of $37 million, more than doubling the loss from Q1 2024 [10]. Market Reaction - Following the announcement of disappointing financial results, 3D Systems' stock price fell significantly, closing at $2.15 per share on March 27, 2025, and further dropping to $1.87 per share on May 13, 2025 [9][11]. - Analysts expressed skepticism about the company's ability to achieve profitability in the near term, citing shrinking revenues and low investor interest in the sector [12].

Core Viewpoint - A class action lawsuit has been filed against 3D Systems Corporation and certain officers for alleged violations of federal securities laws during the Class Period from August 13, 2024, to May 12, 2025, seeking damages for misleading statements regarding the company's business and operations [1][6][7]. Company Overview - 3D Systems provides 3D printing and digital manufacturing solutions across various regions, earning revenue from two segments: Healthcare Solutions and Industrial Solutions [3]. - The Healthcare Solutions segment includes dental, medical devices, personalized health services, and a Regenerative Medicine Program focused on additive manufacturing for human organ transplantation [4]. Financial Performance - In Q4 2024, 3D Systems reported non-GAAP earnings-per-share of -$0.19, missing estimates by $0.08, with sales revenue of $111 million, a 3.4% year-over-year decline [8]. - For the full year 2024, sales were $440.1 million, a 10% decrease from the previous year, attributed to lower hardware systems sales due to macroeconomic factors [8]. - In Q1 2025, revenue was $94.5 million, down 8% year-over-year, with a net loss of $37 million, more than doubling the loss from Q1 2024 [9]. Market Response - Following the Q4 2024 results, 3D Systems' stock price fell by $0.57, or 20.96%, closing at $2.15 per share [8]. - After the Q1 2025 results, the stock price dropped by $0.68, or 26.6%, to close at $1.87 per share [10]. Legal Allegations - The lawsuit alleges that during the Class Period, the company and its officers made materially false and misleading statements, including underestimating the impact of weakened customer spending and overstating the resilience of the business [6][7]. - The updated milestone criteria in the United Partnership were claimed to negatively impact the company's Regenerative Medicine Program revenue [7].

Core Viewpoint - A class action lawsuit has been filed against 3D Systems Corporation and certain officers for alleged violations of federal securities laws during the Class Period from August 13, 2024, to May 12, 2025, seeking damages for misleading statements regarding the company's business and operations [1][8]. Company Overview - 3D Systems provides 3D printing and digital manufacturing solutions across various regions, earning revenue from two segments: Healthcare Solutions and Industrial Solutions [4]. - The Healthcare Solutions segment includes dental, medical devices, personalized health services, and a Regenerative Medicine Program focused on 3D printing organs for transplantation [4][5]. Financial Performance - In March 2025, 3D Systems projected revenue for 2025 to be between $420 million and $435 million, indicating flat to modest growth, with a non-GAAP Gross Profit Margin of 37% to 39% and non-GAAP Operating Expense of $200 million to $220 million [7]. - The company reported a Q4 2024 non-GAAP earnings-per-share of -$0.19, missing estimates, and a sales revenue of $111 million, down 3.4% year-over-year [9]. - For full-year 2024, sales were reported at $440.1 million, a 10% decrease from the previous year, attributed to lower hardware systems sales due to macroeconomic factors [9]. - In Q1 2025, revenue was $94.5 million, down 8% year-over-year, with a net loss of $37 million, more than doubling the loss from Q1 2024 [10]. Market Reaction - Following the announcement of disappointing financial results, 3D Systems' stock price fell significantly, dropping 20.96% to $2.15 per share on March 27, 2025, and further declining 26.6% to $1.87 per share on May 13, 2025 [9][11]. Allegations in Lawsuit - The lawsuit alleges that during the Class Period, the defendants made materially false and misleading statements about the company's business resilience and the impact of weakened customer spending, as well as failing to disclose the negative effects of updated milestone criteria on the Regenerative Medicine Program revenue [8].